NewsResearch
CROSS: What the Esophageal Cancer Trial Found
CROSS tested neoadjuvant chemoradiation vs surgery alone in esophageal cancer, measuring overall survival. Plain-language summary of a result widely described as practice-influencing — and what it doesn't mean.
Original commentary from the Cancer Explained editorial team.
Historical context: this page explains an event dated 2012. It was published as an explainer on July 12, 2026 and is not breaking news.
Please note: this page is educational only — it is not medical advice, and it does not speculate about anyone’s health beyond reliable public reporting. For questions about your own health, talk with your healthcare team.
The question on the table
Surgery to remove part of the esophagus is a major operation. For years, the open question was whether treating the tumor before that operation was worth it.
CROSS was run in the Netherlands to answer it. The name stands for Chemoradiotherapy for Oesophageal Cancer Followed by Surgery Study. Patients with tumors that could be removed were assigned at random to one of two paths: surgery alone, or five weeks of chemotherapy plus radiation first, then surgery.
Who took part
The trial enrolled 368 people between March 2004 and December 2008, and analyzed 366. Of those, 178 got treatment before surgery and 188 went straight to surgery.
Tumor types mattered. About 75 percent had adenocarcinoma, which starts in gland cells and is the common type in the United States and northern Europe. About 23 percent had squamous cell carcinoma, which starts in the flat cells lining the esophagus.
What the treatment was
Treatment before surgery is called neoadjuvant. In CROSS it meant weekly carboplatin and paclitaxel, two chemotherapy drugs, given for five weeks alongside radiation of 41.4 Gy in 23 fractions. A fraction is a single daily dose of radiation. Then surgery.
The doses were deliberately modest. The aim was to shrink the tumor without leaving people too unwell to have the operation. Our page on radiation therapy explains what daily treatment involves.
What the trial found
Two results stand out.
The first is about the operation itself. A complete removal, with no tumor within one millimeter of the cut edges, was achieved in 92 percent of the chemoradiation group against 69 percent of the surgery-alone group. Surgeons call this an R0 resection, and it is the difference between taking all of a cancer out and probably leaving some behind.
The second is survival. Median overall survival was 49.4 months with chemoradiation and surgery, against 24.0 months with surgery alone. The hazard ratio was 0.657, meaning the risk of death at any moment was about a third lower. The p-value was 0.003.
In 47 of 161 people who had surgery after chemoradiation, or 29 percent, the pathologist found no remaining cancer in the removed tissue at all.
Whether it held up
It did. NCI's health-professional summary reports the long-term follow-up at a median of 84 months. Median overall survival was 48.6 months with chemoradiation against 24 months with surgery alone, with a hazard ratio of 0.68.
NCI also breaks the result down by tumor type. For squamous cell carcinoma, median survival was 81.6 months against 21.1 months. For adenocarcinoma, it was 43.2 months against 27.1 months. Both groups gained. The squamous group gained more, and 49 percent of them had no cancer left in the specimen, against 23 percent of the adenocarcinoma group.
NCI's summary states that CROSS definitively demonstrated a survival benefit for preoperative chemoradiation compared with surgery alone.
What that means for a person facing this
Toxic effects were reported and were mostly manageable. The most common serious blood problems were low white cell counts, at 6 percent and 2 percent. The most common other problems were loss of appetite at 5 percent and fatigue at 3 percent. Complications after surgery were similar in the two groups, and in-hospital death was 4 percent in both.
That last figure is the honest one. Esophageal surgery carries real risk either way. Adding treatment beforehand did not add to it here.
Where esophageal cancer stands
The American Cancer Society projects about 22,530 new cases and 16,290 deaths in the United States for 2026, the projection SEER carries. Five-year relative survival is 22.2 percent overall for people diagnosed from 2016 to 2022.
Stage at diagnosis drives that. Only 19 percent of cases are found while still local, where five-year relative survival is 48.6 percent. It is 29.1 percent for regional disease and 5.3 percent once the cancer is distant, which is how 39 percent of cases are found. NCI's stage figures cover diagnoses from 2016 through 2022. These are group averages, not individual predictions.
Symptoms that should not wait
NCI lists these signs of esophageal cancer:
- painful or difficult swallowing.
- weight loss.
- pain behind the breastbone.
- hoarseness and cough.
- indigestion and heartburn.
- a lump under the skin.
Trouble swallowing solid food is the one to act on fast. If food feels like it sticks, or you have started cutting meat smaller or avoiding bread, book an appointment. Long-standing heartburn that changes character also deserves a look. Our guides to esophageal cancer and esophageal cancer symptoms cover what the tests involve.
What this trial cannot tell you
- CROSS compared chemoradiation plus surgery against surgery alone. It did not compare it with chemotherapy before and after surgery, which is another accepted approach.
- Everyone enrolled had a tumor judged removable. The results do not apply to disease that has already spread.
- Median survival is the midpoint of a group. Half did better, half did worse.
- The trial ran from 2004 to 2008. Surgery, imaging, and drug options have all moved since.
Sources
- van Hagen P, et al., N Engl J Med 2012 — CROSS abstract via NCBI E-utilities
- NCI: Esophageal Cancer Treatment (PDQ) — Health Professional Version
- NCI: Esophageal Cancer Symptoms
- SEER Cancer Stat Facts: Esophageal Cancer
How this page was made
An AI-assisted editorial system helped prepare this page. This article has not been reviewed by a healthcare professional unless a named reviewer is specifically shown. Cancer Explained is published by the National Cancer Information Foundation as a nonprofit-oriented public-interest education project. It is not a diagnostic service, does not recommend treatments, and is not for emergencies.
Found an error, a broken source link, outdated information, or wording that feels insensitive? Report it here — we log and act on material corrections.
Know someone who needs this?
Plenty of people are looking for something like this and do not know where to start. If this would help a friend or someone you love, send it on — we have written an opening line so you do not have to stare at an empty message. You can change every word of it.
Your message is written and sent in your own email or messaging app — we never see who you send it to, and nothing is added to any list.
Put the story in context
Prevention, possible warning signs, screening, and diagnosis
This story relates to Esophageal cancer. The information below is general: it does not reveal anything else about a public person’s health, and not every point applies to every cancer. Personal advice depends on age, symptoms, family history, exposures, and medical history.
Prevention and risk reduction
Not every cancer can be prevented. Avoiding tobacco, protecting skin from ultraviolet radiation, limiting alcohol, staying active, and receiving recommended HPV or hepatitis B vaccination can lower the risk of certain cancers. A risk factor is not a prediction or a cause in one individual.
Symptoms and possible early signs
Possible signs vary and are often caused by conditions other than cancer. Changes worth discussing include a new lump, unexplained bleeding or weight loss, a persistent cough, lasting bowel or bladder changes, a changing skin spot, or symptoms that persist or worsen. Some early cancers cause no symptoms.
Screening and early detection
Screening looks for certain cancers before symptoms begin. Recommended tests exist only for some cancers and depend on age and risk. Screening can have benefits and harms; it is not the same as evaluating a new symptom, and there is no single routine scan or blood test that reliably screens for every cancer.
How cancer is diagnosed
Diagnosis may involve a history and exam, imaging, laboratory tests, and often a biopsy. Pathology can identify the cancer type and may test biomarkers that guide treatment. Symptoms, screening results, tumor markers, or online stories alone cannot confirm cancer.
Learn about this story’s cancer topic
A public story may encourage questions, but it should not be used to estimate your risk or choose testing. Contact a healthcare professional about a persistent or concerning change. Seek urgent care for severe or rapidly worsening symptoms.